-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Prelude Therapeutics Inc quarterly/annual Operating Income (Loss) history and growth rate from Q3 2019 to Q2 2024.
- Prelude Therapeutics Inc Operating Income (Loss) for the quarter ending June 30, 2024 was -$37.2M, a 14.7% decline year-over-year.
- Prelude Therapeutics Inc Operating Income (Loss) for the twelve months ending June 30, 2024 was -$142M, a 13.5% decline year-over-year.
- Prelude Therapeutics Inc annual Operating Income (Loss) for 2023 was -$132M, a 7.07% decline from 2022.
- Prelude Therapeutics Inc annual Operating Income (Loss) for 2022 was -$124M, a 8.62% decline from 2021.
- Prelude Therapeutics Inc annual Operating Income (Loss) for 2021 was -$114M, a 93.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)